State-of-the-Art Lecture: Treatment of hepatitis C

2009 ◽  
pp. 105-119
Author(s):  
I. Mederacke ◽  
M. Cornberg ◽  
H. Wedemeyer ◽  
M. P. Manns
Keyword(s):  
Hepatitis C ◽  
State Of The Art

scholarly journals Hepatitis C virus drug resistance-associated substitutions: State of the art summary

Hepatology ◽  
2015 ◽  
Vol 62 (5) ◽  
pp. 1623-1632 ◽  
Author(s):  
Erik Lontok ◽  
Patrick Harrington ◽  
Anita Howe ◽  
Tara Kieffer ◽  
Johan Lennerstrand ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
State Of The Art

Hepatitis-C-Therapie: State of the Art 2018

2018 ◽  
Vol 143 (24) ◽  
pp. 1784-1788
Author(s):  
Stefan Zeuzem
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Rna Polymerase ◽  
State Of The Art

Was ist neu? Ziele der antiviralen Therapie Ziel der individuellen antiviralen Therapie ist die dauerhafte Viruseradikation, populationsbezogen die Elimination des Hepatitis-C-Virus (HCV) (Ziel der WHO bis 2030). Antivirale Medikamente und Medikamenteninteraktionen Zur antiviralen Therapie stehen Inhibitoren der RNA-abhängigen RNA-Polymerase, der NS3/4A-Protease und des NS5A-Proteins des HCV sowie Ribavirin zur Verfügung. Typischerweise werden 2 spezifische Inhibitoren kombiniert, die Therapiedauer liegt für die Mehrheit der Patienten bei 8 – 12 Wochen. Pan-genotypische und Genotypen-restringierte Kombinationstherapien Zwei pan-genotypische Kombinationstherapien stehen zur Verfügung: Sofosbuvir/Velpatasvir sowie Glecaprevir/Pibrentasvir. In der Differenzialtherapie sind die Leber- und Nierenfunktion sowie Medikamenteninteraktionen zu berücksichtigen. Die dauerhaften virologischen Ansprechraten liegen über 95 %, die Sicherheit und Verträglichkeit der Medikamente ist sehr gut. Therapie spezieller Patientenpopulationen Protease-Inhibitoren sind bei Patienten mit einer dekompensierten Zirrhose kontraindiziert. Sofosbuvir ist bei Patienten mit schwerer Niereninsuffizienz nicht zugelassen. Die Re-Therapie von Nonrespondern auf die Interferon-freie Therapie erfolgt mit Sofosbuvir/Velpatasvir/ Voxilaprevir.

scholarly journals State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization

2016 ◽  
Vol 2016 ◽  
pp. 1-19 ◽  
Author(s):  
Cecilia Trucchi ◽  
Andrea Orsi ◽  
Cristiano Alicino ◽  
Laura Sticchi ◽  
Giancarlo Icardi ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Low Income ◽  
State Of The Art ◽  
Antiviral Agents ◽  
Screening Strategy ◽  
New Drugs ◽  
Low Income Countries ◽  
Effective Control ◽  
Future Research

Hepatitis C virus (HCV) still represents a major public health threat, with a dramatic burden from both epidemiological and clinical points of view. New generation of direct-acting antiviral agents (DAAs) has been recently introduced in clinical practice promising to cure HCV and to overcome the issues related to the interferon-based therapies. However, the emergence of drug resistance and the suboptimal activity of DAAs therapies against diverse HCV genotypes have been observed, determining treatment failure and hampering an effective control of HCV spread worldwide. Moreover, these treatments remain poorly accessible, particularly in low-income countries. Finally, effective screening strategy is crucial to early identifying and treating all HCV chronically infected patients. For all these reasons, even though new drugs may contribute to impacting HCV spread worldwide a preventive HCV vaccine remains a cornerstone in the road to significantly reduce the HCV spread globally, with the ultimate goal of its eradication. Advances in molecular vaccinology, together with a strong financial, political, and societal support, will enable reaching this fundamental success in the coming years. In this comprehensive review, the state of the art about these major topics in the fight against HCV and the future of research in these fields are discussed.

Treating hepatitis C: the state of the art

2004 ◽  
Vol 33 (1) ◽  
pp. 1-9 ◽  
Author(s):  
Robert G. Gish
Keyword(s):  
Hepatitis C ◽  
State Of The Art ◽  
The State

scholarly journals Hepatitis C pharmacogenetics: State of the art in 2010

Hepatology ◽  
2011 ◽  
Vol 53 (1) ◽  
pp. 336-345 ◽  
Author(s):  
Nezam H. Afdhal ◽  
John G. McHutchison ◽  
Stefan Zeuzem ◽  
Alessandra Mangia ◽  
Jean-Michel Pawlotsky ◽  
...  
Keyword(s):  
Hepatitis C ◽  
State Of The Art

scholarly journals Hepatitis C Infection: Its Sequelaie and Outcomes – State-of-the-Art Workshop, September 24 to 25, 1998

2000 ◽  
Vol 14 (suppl b) ◽  
pp. 49B-59B
Author(s):  
Association for Study of the Liver (CASL)
Keyword(s):  
United States ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Natural History ◽  
Chronic Hepatitis C ◽  
State Of The Art ◽  
The United States ◽  
Hcv Infection ◽  
Hepatitis C Infection ◽  
Consensus Statements

This report summarizes a state-of the- art workshop held in September 1998 on the “Natural History and Outcome of Hepatitis C Infection”. Sixteen Canadian and two internationally renowned hepatologists were invited. A practical classification of HCV infection served as a framework for the meeting. The concepts of modelling of chronic disease, the epidemiology of HCV infection before the introduction of anti-HCV testing, and the outcome of various forms of chronic hepatitis C in adults and children were presented. Lectures on the outcome of HCV cirrhosis, hepatocellular carcinoma, the role of liver transplantation, the influence of host factors on outcome, iron overload in chronic hepatitis C and possible modification of the natural history by antiviral therapy were followed by discussion and consensus statements pertaining to each presentation. “The European Experience in Assessing Chronic Hepatitis C” was presented by Prof G Dusheiko from the United Kingdom, and Prof Leonard Seeff from the National Institutes of Health (United States) presented “The Epidemiology and Outcome of Hepatitis C Infection in the United States and the World”.

Sign in / Sign up

Export Citation Format

Share Document